Standing up shouldn't feel like running a sprint. You are not deconditioned. Your autonomic nervous system is dysregulated.

Salt and fluid loading is first-line non-pharmaceutical treatment for POTS, with strong evidence for symptom reduction. Standard recommendations are 8–10 grams of sodium per day (well above standard dietary guidance) and 2–3 liters of fluid. Evidence level: Strong for symptom improvement; this is the foundation everything else builds on.

In practice: salt this aggressively without medical guidance is not appropriate if you have hypertension, kidney disease, or heart failure — get cleared first. Spreading sodium across the day works better than a single dose; many patients use electrolyte products (LMNT, Buoy, Vitassium salt sticks, or homemade with table salt and water) so it's not all from food. Plain water alone can paradoxically worsen symptoms by diluting sodium — pairing fluid with sodium is the point. A useful trick: a 16 oz bolus of cold water in 5 minutes acutely raises blood pressure for ~30 minutes (the "water bolus effect") and can be used before standing tasks. Track what works. If 6 g sodium feels different from 10 g, that's information.

Yes — for most POTS patients, compression meaningfully reduces symptoms. The mechanism is straightforward: in POTS, blood pools in the lower body when standing, reducing venous return and triggering the compensatory heart rate increase. External compression counteracts the pooling. Evidence level: Moderate to Strong, particularly for abdominal compression.

Key detail most patients aren't told: knee-high compression alone is generally not enough. The most effective compression is waist-high or abdominal binders, because the abdominal/splanchnic circulation is where the largest pooling occurs. Compression strength of 20–30 mmHg or 30–40 mmHg is typical; lower strengths (15–20 mmHg) are easier to tolerate but less effective. Brands like Juzo, Sigvaris, Mediven, and CEP make medical-grade options. Abdominal binders from POTS-aware sources work for some patients. It's worth wearing them for the activities that trigger symptoms — running errands, work, exercise — even if not all day. They're hot and unsexy and they work.

POTS isn't one disease — it's a syndrome with several mechanisms. The three commonly referenced subtypes (note: many patients have features of more than one): Hyperadrenergic POTS — characterised by elevated standing norepinephrine (above 600 pg/mL is a common cutoff), tremor, anxiety-feeling symptoms, blood pressure that rises rather than drops on standing. Treatment leans toward central sympathetic dampeners — clonidine, methyldopa, sometimes beta blockers, and ivabradine.

Neuropathic POTS — caused by partial autonomic neuropathy, often with small fiber neuropathy on biopsy, peripheral pooling and cold/discoloured legs on standing. Treatment leans toward midodrine (vasoconstrictor), pyridostigmine, droxidopa, and aggressive volume expansion. Hypovolemic POTS — characterised by reduced blood volume; treatment emphasises salt, fluids, and sometimes fludrocortisone for sodium retention. Evidence level for the subtypes themselves: Moderate; clinical utility is real but boundaries are fuzzy. A standing plasma norepinephrine, autoimmune autonomic panel, and small fiber neuropathy biopsy can clarify which mechanism dominates. Most general cardiologists won't run these tests; an autonomic specialist will.

There's no single best medication — it depends on subtype and presentation. Beta blockers (propranolol, metoprolol, often at low doses like 10–20 mg) are widely used and have moderate evidence; they work by blunting the heart rate response. They can worsen fatigue and cause hypotension in some patients. Evidence level: Moderate.

Ivabradine has become a preferred first-line in many specialty centers because it lowers heart rate without affecting blood pressure or causing the fatigue that beta blockers can. Multiple trials and observational studies show meaningful symptom improvement, with a randomised trial (Taub et al, 2021) showing benefit in hyperadrenergic POTS. Evidence level: Strong for hyperadrenergic phenotype. Insurance coverage in the US can be a fight — it's FDA-approved for heart failure, used off-label for POTS. Midodrine is a peripheral vasoconstrictor that helps neuropathic POTS most; it's typically dosed three times a day during waking hours and can cause goosebumps and scalp tingling. Pyridostigmine (Mestinon) has interesting evidence for orthostatic intolerance and ME/CFS overlap. Fludrocortisone for volume expansion is older and used less now due to side effects. The right answer often involves trying medications stepwise, with a clinician who's seen enough POTS patients to read the response correctly.

POTS is one of the most common Long COVID phenotypes and one of the most common ME/CFS comorbidities — present in roughly 25–50% of ME/CFS patients depending on the cohort. The clinical overlap is enough that many patients meet criteria for all three. Post-viral POTS, including from EBV, COVID-19, and other infections, has been described in the literature for decades; COVID-19 just made it visible to mainstream medicine. Evidence level: Strong for the overlap.

Why it matters clinically: if you have post-exertional malaise (worsening of all symptoms 12–48 hours after exertion), the ME/CFS-style approach to pacing matters even if cardiology is your primary care site. Pushing through with traditional POTS exercise rehabilitation can trigger PEM crashes for patients with overlap. Recumbent reconditioning protocols (the Levine/CHOP/Dallas protocols) can work — but they require modification when ME/CFS features are present, and rapid progression often backfires. A clinician who treats both is rare; if you only have a cardiologist, you may need to bring the ME/CFS framework yourself or add a Long COVID or ME/CFS-literate physician.

Diagnosis of POTS requires a sustained heart rate increase of 30+ bpm in adults (40+ in adolescents) within 10 minutes of standing, without significant blood pressure drop, and orthostatic symptoms — for at least 3 months. This can be diagnosed with a 10-minute active stand test (heart rate measured lying down, then at 1, 3, 5, and 10 minutes upright) in a clinic, often without specialised equipment. A tilt table test is more controlled and is useful when active stand is equivocal, when syncope/near-syncope is the dominant symptom, or to help distinguish POTS from other forms of orthostatic intolerance like vasovagal syncope and orthostatic hypotension.

More extensive autonomic testing — QSART (sweat function), Valsalva ratio, deep breathing heart rate variability, supine and standing catecholamines, plasma volume measurement, small fiber neuropathy biopsy — is offered at autonomic specialty centers (Vanderbilt, Mayo, Cleveland Clinic, Johns Hopkins, and several academic centers). It's worth pushing for if your subtype is unclear, you've failed first-line treatment, you suspect autoimmune autonomic neuropathy, or your case has unusual features. A general cardiologist who confirms POTS on a stand test and starts standard treatment is reasonable for many patients; a referral to an autonomic specialist is reasonable when standard treatment isn't working.